Note 5 - Inventory

12 Months Ended

Dec. 31, 2021

Notes to Financial Statements

Inventory Disclosure [Text Block]

Note 5 – Inventory

At December 31, 2021 and 2020, the Company’s inventory primarily related to ORLADEYO. Additionally, inventory included RAPIVAB and peramivir, which is manufactured for the Company’s partners.

The Company’s inventories consisted of the following:

	December 31,
	2021			2020
Raw materials	$	5,658		$	206
Work-in-process		9,669			2,555
Finished goods		709			4,548
Total inventory	$	16,036		$	7,309
Reserves		(245	)		(270	)
Total inventory, net	$	15,791		$	7,039